Sickle cell disease (SCD) is an inherited blood disorder that affects the red blood cells and occurs when a person has inherited a sickle cell gene from each parent. Healthy red blood cells are flexible so that they can move through the smallest blood vessels. In sickle cell disease, the hemoglobin is abnormal, causing the red blood cells to be rigid and shaped like a 'C' or sickle, the shape from which the disease takes its name. Sickle cells can get stuck and block blood flow, causing pain and infections. Complications of sickle cell disease occur because the sickled cells block blood flow to specific organs. The worst complications include stroke, acute chest syndrome (a condition that lowers the level of oxygen in the blood), anemia, organ damage, other disabilities, and even premature death.
This report covers 1mm (US) and provides an Excel-based forecast model for the Sickle Cell Disease market through 2030.
This report covers 1mm (US) and provides an Excel-based forecast model for the Sickle Cell Disease market through 2030.
Key Highlights
- Forecast includes one country
- Forecast covers three time points: base year, 5-year, and 10-year
Scope
- The publisher's Sickle Cell Disease Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020 - 2030 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the global SCD market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SCD market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Table of Contents
1 Executive Summary2 Disease Overview
3 Epidemiology
4 Current Treatment Options
5 Unmet Needs and Opportunities
6 Pipeline Assessment
7 R&D Strategies
8 Market Outlook
9 Appendix
10 Contact the Publisher
List of Tables
Table 1. Marketed Products
Table 2. Leading Pipeline Agents
Table 3. Pipeline Products: FDA Review Designations
List of Figures
Figure 1: Summary of Key Findings
Figure 2. Treatment Paradigm
Figure 3. Unmet Needs
Figure 4. Pipeline Overview
Figure 5. Clinical Trials Overview
Figure 6. Market Forecast
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol Myers Squibb
- Emmaus Life Sciences
- Global Blood Therapeutics
- Novartis Pharmaceuticals
- bluebird bio
- Genmab/Roche
- Forma Therapeutics
- Agios Pharmaceuticals
- H.Lundbeck/Imara
- CRISPR/Vertex
- Editas Medicine
- Graphite Bio
- Sangamo/Sanofi
- Bioverativ
